DGF knows nothing about running a cannabis pharma company. Everyone that had anything to do with this company is gone. The inexperienced ownership makes 99.9% of the decisions, the investors make .001%. The only approved market is Israel for the cream, and that is whenever they figure out how to package and deliver a product. Companies are already out with tablets-and there are YEARS ahead for any US approvals for any product. Yep, a great investment. Maybe all the AP*PL investors should sell their holdings and come here.
All information provided is the opinion of this poster from review of information in the public domain.